Pancragen — Research, Dosing & Price Guide

Pancragen is a bioregulator peptide (Lys-Glu-Asp-Trp) developed by the Khavinson laboratory that targets pancreatic tissue. It is designed to support normal pancreatic function, including both exocrine (digestive enzyme) and endocrine (insulin/glucagon) activity. It works at the epigenetic level to normalize gene expression in aging or damaged pancreatic cells.

Pancragen is a tetrapeptide that penetrates cell membranes and interacts with DNA sequences in pancreatic cells, modulating gene expression related to insulin synthesis, beta-cell regeneration, and digestive enzyme production. It normalizes the production of key pancreatic proteins including insulin, glucagon, and pancreatic lipase. The peptide also has anti-inflammatory effects on pancreatic tissue, reducing local cytokine production that contributes to islet cell damage. Like other Khavinson bioregulators, Pancragen works through gradual epigenetic modulation rather than immediate receptor-mediated signaling.

• Khavinson et al. demonstrated Pancragen restored insulin production capacity in aged animal pancreatic tissue
• Studies showed the tetrapeptide Lys-Glu-Asp-Trp regulated gene expression in pancreatic cell cultures, normalizing protein synthesis patterns
• Preclinical research showed improved glucose tolerance in diabetic animal models after Pancragen administration
• Research in Bulletin of Experimental Biology and Medicine showed reduced inflammatory markers in pancreatic tissue

• Oral: 10–20 mg daily in capsule form for 10–30 days
• Repeat cycles every 3–6 months
• Can be taken with or without food
• For metabolic support: 20 mg daily for 20–30 days
• For maintenance: 10 mg daily for 10 days every 4–6 months

Known Side Effects

• No significant adverse effects reported in published research
• Mild GI discomfort — infrequently reported
• Theoretical risk of hypoglycemia if combined with insulin or sulfonylureas due to enhanced beta-cell function
• Very limited clinical safety data

Safety Profile

Pancragen has a favorable safety profile based on the Khavinson bioregulator research framework. As a naturally occurring tetrapeptide sequence, it is expected to have low toxicity. No serious adverse events have been reported. However, human clinical trial data is very limited. Individuals with type 1 or type 2 diabetes should monitor blood glucose carefully if using Pancragen, as enhanced beta-cell function could alter insulin requirements. Coordination with a physician is recommended for diabetic patients.

Days 1–10: No immediate subjective effects. Epigenetic modulation of pancreatic gene expression is occurring at the cellular level. Days 10–30: Improved blood glucose stability may become measurable. Some users report improved digestion, particularly fat digestion, suggesting exocrine pancreatic support. Post-cycle: Benefits persist for weeks to months as the gene expression changes continue to influence pancreatic protein synthesis. Repeated cycles provide cumulative benefit.

Prices sourced from peptides.gg marketplace. Prices may vary.